Literature DB >> 20308476

Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy.

Courtney A Woodfield1, Glenn A Tung, David J Grand, John A Pezzullo, Jason T Machan, Joseph F Renzulli.   

Abstract

OBJECTIVE: The objective of our study was to determine the relationship between the apparent diffusion coefficient (ADC) value on diffusion-weighted imaging (DWI) and Gleason score of prostate cancer and percentage of tumor involvement on prostate core biopsy.
MATERIALS AND METHODS: We performed a retrospective study of 57 patients with biopsy-proven prostate cancer who underwent endorectal MRI with DWI between July 2007 and March 2008. Regions of interest (ROIs) were drawn on ADC maps at sites of visible tumor on DW images and ADC maps. A hierarchic mixed linear model was used to compare the ADC value of prostate cancer with the Gleason score and the percentage of tumor on core biopsy.
RESULTS: Eighty-one sites of biopsy-proven prostate cancer were visible on DW images and ADC maps. The least-squares mean ADC for disease with a Gleason score of 6 was 0.860 x 10(-3) mm(2)/s (standard error of the mean [SEM], 0.036); Gleason score of 7, 0.702 x 10(-3) mm(2)/s (SEM, 0.030); Gleason score of 8, 0.672 x 10(-3) mm(2)/s (SEM, 0.057); and Gleason score of 9, 0.686 x 10(-3) mm(2)/s (SEM, 0.067). Differences between the mean ADC values for a prostate tumor with a Gleason score of 6 and one with a Gleason score of 7 (p = 0.0096) and for a prostate tumor with a Gleason score of 6 and one with a Gleason score of 8 (p = 0.0460) were significant. Comparison between the ADC and percentage of tumor on core biopsy showed a mean ADC decrease of 0.006 (range, 0.004-0.008 x 10(-3) mm(2)/s) for every 1% increase in tumor in the core biopsy specimen.
CONCLUSION: DWI may help differentiate between low-risk (Gleason score, 6) and intermediate-risk (Gleason score, 7) prostate cancer and between low-risk (Gleason score, 6) and high-risk (Gleason score > 7) prostate cancer. There is an inverse relationship between the ADC and the percentage of tumor involvement on prostate core biopsies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308476     DOI: 10.2214/AJR.09.2651

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  61 in total

1.  Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.

Authors:  Hashim U Ahmed; Oguz Akin; Jonathan A Coleman; Sarah Crane; Mark Emberton; Larry Goldenberg; Hedvig Hricak; Mike W Kattan; John Kurhanewicz; Caroline M Moore; Chris Parker; Thomas J Polascik; Peter Scardino; Nicholas van As; Arnauld Villers
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

Review 2.  Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria.

Authors:  Michael R Abern; Matvey Tsivian; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

3.  Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer.

Authors:  Hyeyeol Bae; Soichiro Yoshida; Yoh Matsuoka; Hiroshi Nakajima; Eisaku Ito; Hiroshi Tanaka; Miyako Oya; Takayuki Nakayama; Hideki Takeshita; Toshiki Kijima; Junichiro Ishioka; Noboru Numao; Fumitaka Koga; Kazutaka Saito; Takumi Akashi; Yasuhisa Fujii; Kazunori Kihara
Journal:  Int Urol Nephrol       Date:  2014-03       Impact factor: 2.370

4.  Reducing the influence of b-value selection on diffusion-weighted imaging of the prostate: evaluation of a revised monoexponential model within a clinical setting.

Authors:  Yousef Mazaheri; Hebert Alberto Vargas; Oguz Akin; Debra A Goldman; Hedvig Hricak
Journal:  J Magn Reson Imaging       Date:  2011-11-08       Impact factor: 4.813

Review 5.  Current trends and new frontiers in focal therapy for localized prostate cancer.

Authors:  Melissa H Mendez; Daniel Y Joh; Rajan Gupta; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2015-06       Impact factor: 3.092

Review 6.  [Diffusion-weighted MRI of the prostate].

Authors:  U G Mueller-Lisse; U L Mueller-Lisse; P Zamecnik; H-P W Schlemmer; M K Scherr
Journal:  Radiologe       Date:  2011-03       Impact factor: 0.635

7.  Development of a Combined MR Fingerprinting and Diffusion Examination for Prostate Cancer.

Authors:  Alice C Yu; Chaitra Badve; Lee E Ponsky; Shivani Pahwa; Sara Dastmalchian; Matthew Rogers; Yun Jiang; Seunghee Margevicius; Mark Schluchter; William Tabayoyong; Robert Abouassaly; Debra McGivney; Mark A Griswold; Vikas Gulani
Journal:  Radiology       Date:  2017-02-10       Impact factor: 11.105

8.  Information of prostate biopsy positive core: does it affect MR detection of prostate cancer on using 3T-MRI?

Authors:  Rika Yoshida; Yasushi Kaji; Yukihisa Tamaki; Takashi Katsube; Hajime Kitagaki; Tsunehito Kanbara; Takao Kamai
Journal:  Jpn J Radiol       Date:  2015-03-12       Impact factor: 2.374

9.  Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study.

Authors:  Flavie Bratan; Emilie Niaf; Christelle Melodelima; Anne Laure Chesnais; Rémi Souchon; Florence Mège-Lechevallier; Marc Colombel; Olivier Rouvière
Journal:  Eur Radiol       Date:  2013-03-15       Impact factor: 5.315

Review 10.  Functional MR Imaging Techniques in Oncology in the Era of Personalized Medicine.

Authors:  Matthias R Benz; Hebert Alberto Vargas; Evis Sala
Journal:  Magn Reson Imaging Clin N Am       Date:  2015-09-26       Impact factor: 2.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.